Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials
Analysis of six randomized phases 3 trials were done to investigate non-inferiority of 3 months versus 6 months of adjuvant chemotherapy. For patients treated with CAPOX, 5-year overall survival was 82% versus 81% for those treated with FOLfox. This conclusion is strengthened by the substantial reduction of toxicities, inconveniencies, and cost associated with shorter treatment duration.
